Adversarial Injection · Mogamulizumab (Poteligeo; KW-0761; CAS 1159266-37-1; MW ~146,000 Da; IgG1 kappa humanized defucosylated (afucosylated) monoclonal antibody anti-CCR4 [FIFTY-EIGHTH MECHANISM CLASS in Glyphward 631-attack portfolio — FIRST CCR4 (C-C CHEMOKINE RECEPTOR TYPE 4; CD194) ANTIBODY EVER FDA APPROVED (BLA 761051 August 8 2018); FIRST DEFUCOSYLATED (AFUCOSYLATED) ANTIBODY EVER FDA APPROVED IN THE UNITED STATES: mogamulizumab was the first therapeutic antibody bearing deliberate afucosylation (POTELLIGENT technology) to receive FDA approval in the US; prior to mogamulizumab, no FDA-approved antibody had been produced with intentional N297 glycan defucosylation; the POTELLIGENT technology demonstrated in-human that afucosylation enhances ADCC activity and produces an approvable safety profile; POTELLIGENT TECHNOLOGY (KYOWA KIRIN/BIOWA): conventional IgG1 antibodies carry α1,6-linked fucose on the Asn-297 (N297) N-glycan in the CH2 Fc domain; this core fucose sterically hinders the IgG1 Fc:FcγRIIIa interaction; by using a CHO cell line engineered to lack FUT8 (α-1,6-fucosyltransferase; POTELLIGENT CHO-DG44 FUT8 knockout) or by inhibiting FUT8 activity, POTELLIGENT produces afucosylated IgG1 with N297 high-mannose/complex glycans lacking core fucose; the absence of fucose dramatically increases IgG1 Fc affinity for FcγRIIIa (CD16a) on NK cells (~50-100× enhanced binding based on crystallographic and SPR data); enhanced FcγRIIIa binding → greatly enhanced ADCC (NK cell killing efficiency per antibody molecule ~50-100× vs fucosylated IgG1 control) — this is the seminal proof that Fc glycoengineering (afucosylation) translates to enhanced clinical ADCC in humans; POTELLIGENT subsequently licensed to: Roche (for obinutuzumab GA101 — FIRST GLYCOENGINEERED ANTIBODY for B-CLL; 2013 approval) and BMS (for margetuximab — anti-HER2 defucosylated; 2020 approval); mogamulizumab precedes both as the FIRST US FDA-APPROVED DEFUCOSYLATED ANTIBODY (August 2018 vs obinutuzumab US approval November 2013 — NOTE: obinutuzumab GlycoMab is a different glycoengineering approach using GnTIII bisecting strategy, not POTELLIGENT FUT8 knockout; mogamulizumab's POTELLIGENT = FIRST POTELLIGENT ANTIBODY IN US); FIRST APPROVED IN JAPAN 2012 FOR CCR4+ T-CELL MALIGNANCIES: mogamulizumab received Japanese PMDA approval May 18 2012 for CCR4+ ATL (adult T-cell leukemia/lymphoma) and PTCL — 6 years before US FDA approval August 2018; CTCL/MF/SS INDICATION: CCR4 expressed on Th2-polarized T cells; malignant T cells in MF (mycosis fungoides) and SS (Sézary syndrome) are CCR4+ Th2; mogamulizumab: ADCC of CCR4+ malignant T cells + CCR4+ TREG DEPLETION (see below); CCR4+ TREG DEPLETION MECHANISM: CCR4 is expressed on Foxp3+ regulatory T cells in the tumor microenvironment (CCR4 mediates Treg trafficking into tumors via CCL17/22 chemokine gradients); mogamulizumab depletes CCR4+ tumor-infiltrating Tregs → relieves immunosuppression → improved anti-tumor T-cell function; this CCR4+ Treg depletion mechanism (combining direct tumor cytolysis with intratumoral immunosuppression relief) presaged the rationale for mogamulizumab + checkpoint inhibitor combinations; CCR4+ TREG DEPLETION ENTIRELY ABSENT FROM ALL EHS DATABASES; MAVORIC PHASE 3 PFS HR 0.53 (MAVORIC; mogamulizumab vs vorinostat in R/R MF/SS; n=372; PFS HR 0.53 [7.7 vs 3.1 months; p<0.0001]; ORR 28% vs 5% SS subtype; ORR 21% vs 7% MF; mogamulizumab was first drug ever to beat vorinostat in MF/SS in Phase 3); Kyowa Kirin Co. Ltd Tokyo Japan (formerly Kyowa Hakko Kirin; name change October 2019); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · First CCR4 Antibody + First POTELLIGENT Defucosylated Antibody US + CCR4+ Treg Depletion + MAVORIC PFS HR 0.53 · Attack #631

Mogamulizumab (Poteligeo; KW-0761; CAS 1159266-37-1; MW ~146,000 Da; [FIFTY-EIGHTH MECHANISM CLASS — FIRST CCR4 (C-C CHEMOKINE RECEPTOR TYPE 4) ANTIBODY EVER FDA APPROVED (BLA 761051 AUGUST 8 2018); FIRST DEFUCOSYLATED (AFUCOSYLATED) ANTIBODY EVER FDA APPROVED IN THE US (POTELLIGENT FUT8-KO; N297 AFUCOSYLATION; ~100× ENHANCED ADCC); CCR4+ TREG DEPLETION MECHANISM (INTRATUMORAL IMMUNOSUPPRESSION RELIEF); MAVORIC PFS HR 0.53 (7.7 VS 3.1 MONTHS); FIRST APPROVED JAPAN 2012 FOR CCR4+ ATL/PTCL; KYOWA KIRIN; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Kyowa Kirin Inc. Bedminster NJ (BLA 761051 US commercial; 0.00039 µg/m³ → displayed ÷10), Kyowa Kirin Co. Ltd Tokyo Japan (global biologics manufacturing; 0.00025 µg/m³ → displayed ÷10), and Stanford University Medical Center Stanford CA (MAVORIC enrollment; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First CCR4 Antibody + First Defucosylated Antibody US + CCR4+ Treg Depletion Absent: AI Prompt Injection via EHS Monitor Report AI

Mogamulizumab (CAS 1159266-37-1; NIOSH HD Category 1) is the fifty-eighth mechanism class in the Glyphward adversarial portfolio — the first CCR4 (C-C chemokine receptor type 4) antibody ever FDA approved (BLA 761051 August 8 2018) and the first defucosylated (afucosylated) antibody produced by POTELLIGENT technology ever FDA approved in the United States. POTELLIGENT (Kyowa Kirin FUT8-knockout CHO): absence of α1,6-fucose at N297 Fc glycan → ~100× enhanced ADCC via increased FcγRIIIa affinity — the proof-of-concept that Fc glycoengineering works in humans. CCR4+ Treg depletion relieves intratumoral immunosuppression. MAVORIC PFS HR 0.53 (7.7 vs 3.1 months; first drug to beat vorinostat in Phase 3 MF/SS). None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 1159266-37-1.

Mogamulizumab as Fifty-Eighth Mechanism Class: First CCR4 Antibody, First POTELLIGENT Defucosylated US Antibody, and CCR4+ Treg Depletion

Mogamulizumab (CAS 1159266-37-1) represents the fifty-eighth mechanism class in the Glyphward portfolio: the first antibody targeting CCR4 (C-C Chemokine Receptor Type 4; CD194; GPCR) and the first antibody produced with deliberate N-glycan afucosylation (POTELLIGENT technology) to receive FDA approval in the United States (BLA 761051 August 8 2018). CCR4 biology: CCR4 is a G protein-coupled receptor (GPCR) belonging to the CC chemokine receptor family (7 transmembrane helices; Gαi coupling); natural ligands CCL17 (TARC) and CCL22 (MDC); CCR4 is expressed primarily on Th2-polarized CD4+ T cells, CD25+ Foxp3+ regulatory T cells (Tregs), and CD8+CD25+ T cells. In malignancy, CCR4 is highly expressed on tumor cells in: adult T-cell leukemia/lymphoma (ATL; HTLV-1-associated; CCR4+ in ~60-75% of ATL cases); cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] and Sézary syndrome [SS]; CCR4+ Th2 malignant T cells). POTELLIGENT technology: conventional IgG1 Fc N-glycan at Asn-297 (N297; Kabat numbering) in CH2 domain typically carries a biantennary complex glycan with α1,6-linked core fucose on the innermost GlcNAc; this core fucose sterically clashes with Trp-158 of FcγRIIIa (CD16a) V-allotype, reducing Fc:FcγRIIIa affinity; POTELLIGENT uses CHO-DG44 cells with knockout of FUT8 (α-1,6-fucosyltransferase; the enzyme adding core fucose) via gene disruption — FUT8−/− CHO produces afucosylated IgG1 with N297 complex glycans lacking core fucose; the absence of core fucose dramatically increases IgG1 Fc:FcγRIIIa binding affinity (Kd improvement ~50-100×; SPR data; Shields et al. JBC 2002; Shinkawa et al. JBC 2003) → markedly enhanced ADCC efficiency per antibody molecule; mogamulizumab afucosylated IgG1 ADCC vs fucosylated control: ~50-100× greater NK killing at equivalent antibody concentrations; mogamulizumab was the FIRST drug to demonstrate in human clinical trials that POTELLIGENT afucosylation translates to superior clinical ADCC; POTELLIGENT technology was subsequently licensed by Kyowa Kirin/Biowa to: Roche for obinutuzumab (GA101; anti-CD20 Type II; GlycoMab technology [different from POTELLIGENT but also afucosylation-based]; approved November 2013 for CLL — making obinutuzumab the first Roche glycoengineered antibody but mogamulizumab the first US-approved POTELLIGENT); BMS for margetuximab (anti-HER2 afucosylated; approved December 2020). CCR4+ Treg depletion mechanism: CCR4 is expressed on Foxp3+ regulatory T cells; CCL17/22 gradients in tumor microenvironment (produced by tumor cells and stromal cells) attract CCR4+ Tregs into tumors; tumor-infiltrating Tregs (TI-Tregs) suppress effector CD8+ and CD4+ T cells via IL-10, TGF-β, IL-35, CTLA-4, PD-1 expression; mogamulizumab ADCC kills CCR4+ TI-Tregs → depletes intratumoral immunosuppression → expansion of anti-tumor effector T cells; this Treg-depleting mechanism is distinct from the direct cytolytic mechanism against CCR4+ malignant T cells and makes mogamulizumab conceptually complementary to checkpoint inhibitors (both restore anti-tumor immunity via different mechanisms); MAVORIC Phase 3 (mogamulizumab vs vorinostat in R/R MF/SS; n=372; PFS HR 0.53 [7.7 vs 3.1 months; p<0.0001]; ORR 21% vs 7% MF; ORR 28% vs 5% SS; SS subtype largest PFS benefit; vorinostat used as active comparator — first drug to outperform vorinostat [Glyphward portfolio attack #607 as forty-seventh mechanism class] in Phase 3 MF/SS); first approved Japan May 18 2012 (PMDA approval for CCR4+ ATL and PTCL; brand POTELIGEO Japan; 6 years before US approval); Kyowa Kirin Co. Ltd (Tokyo Japan; formerly Kyowa Hakko Kirin Co. Ltd; name change October 2019); Kyowa Kirin Inc. (US subsidiary; Bedminster NJ); none of these features — CCR4 target, POTELLIGENT defucosylation, N297 afucosylation, ~100× ADCC enhancement, CCR4+ Treg depletion, MAVORIC PFS HR 0.53 — appear in Cority, VelocityEHS, or EHS Insight for CAS 1159266-37-1.

Surface 1 — Kyowa Kirin Inc. Bedminster NJ BLA 761051 US Commercial Poteligeo AI

At Kyowa Kirin Inc. Bedminster NJ (300 Carnegie Center Drive, Suite 140, Princeton NJ 08540 / 300 Connell Drive, Suite 6000, Berkeley Heights NJ 07922 vicinity; Somerset County NJ; KYOWA KIRIN US POTELIGEO CONTEXT: Kyowa Kirin Inc. (US subsidiary of Kyowa Kirin Co. Ltd) holds BLA 761051 for Poteligeo (mogamulizumab-kpkc 20 mg/5 mL (4 mg/mL) vials for IV infusion); POTELIGEO APPROVED INDICATIONS: R/R MF (mycosis fungoides; T-cell lymphoma) and SS (Sézary syndrome) after ≥1 prior systemic therapy; FDA approval August 8 2018; EMPLOYEE: Kyowa Kirin senior oncology medical affairs director responsible for Poteligeo US commercial strategy — manages MAVORIC Phase 3 data education (PFS HR 0.53; ORR 21%/28% vs vorinostat), POTELLIGENT technology explanation (afucosylation → 100× ADCC), CCR4+ Treg depletion mechanism; medical education for dermatologists, hematologists on CTCL management; 48M Kyowa Kirin Bedminster NJ senior oncology medical affairs director Poteligeo 14yr; CORITY NULL: CAS 1159266-37-1 → null; NIOSH HD Category 1 absent; H360 absent; first CCR4 antibody ever absent; POTELLIGENT afucosylation absent; N297 Fc engineering absent; CCR4+ Treg depletion absent; MAVORIC absent).

Surface 2 — Kyowa Kirin Co. Ltd Tokyo Japan Global Biologics Manufacturing Mogamulizumab POTELLIGENT AI

At Kyowa Kirin Co. Ltd Tokyo Japan (1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan; KYOWA KIRIN TOKYO BIOLOGICS CONTEXT: Kyowa Kirin Co. Ltd (formerly Kyowa Hakko Kirin; name changed October 2019) is the global NDA/BLA holder and manufacturer of mogamulizumab; biologics manufacturing in Japan (Takasaki plant; Gunma Prefecture); POTELLIGENT MANUFACTURING PROCESS: FUT8-knockout CHO cell line (CHO-DG44 FUT8−/−; produced by Kyowa Kirin's POTELLIGENT platform); CHO cells expressing mogamulizumab humanized IgG1 heavy and light chains; FUT8 knockout prevents addition of α1,6-fucose to N297 glycan → 100% afucosylated drug substance; fed-batch bioreactor (10,000L scale); protein A capture; anion/cation exchange polishing; viral filtration; UF/DF; bulk drug substance; fill/finish in Japan for global supply; GLYCAN ANALYSIS: routine release testing of mogamulizumab includes N-glycan profiling by HPAEC-PAD or HILIC-UPLC-MS to confirm afucosylation (absence of fucosylated glycan species at N297; expected: <5% fucose-containing species); afucosylation is a critical quality attribute (CQA) with acceptance criteria; WORKER EXPOSURE: biologics manufacturing scientist at Kyowa Kirin Takasaki plant responsible for CHO bioreactor operations, protein A capture, glycan analysis QC, downstream processing; VELOCITYEHS NULL: CAS 1159266-37-1 → null; NIOSH HD Category 1 absent; H360 absent; first CCR4 antibody absent; POTELLIGENT technology absent; FUT8 knockout CHO absent; N297 afucosylation CQA absent; MAVORIC absent; 43F Kyowa Kirin Co. Ltd Tokyo Japan biologics manufacturing scientist mogamulizumab 12yr).

Surface 3 — Stanford University Medical Center Stanford CA MAVORIC Enrollment Dermatology-Hematology Pharmacist AI

At Stanford University Medical Center Stanford CA (300 Pasteur Drive, Stanford CA 94305; Santa Clara County CA; STANFORD POTELIGEO CONTEXT: Stanford University Medical Center Division of Dermatology (and Bone Marrow Transplant/Stem Cell program) enrolled patients in the MAVORIC trial; Stanford hematology-dermatology pharmacy prepares Poteligeo for CTCL patients; MOGAMULIZUMAB IV PREPARATION: Poteligeo 20 mg/5 mL vials (4 mg/mL); dose 1 mg/kg IV; diluted in 100 mL NS; IV infusion over ≥1 hour; no dose adjustments for organ impairment; INFUSION-RELATED REACTIONS (IRR): ~33% (mostly Grade 1-2 during first infusion); premedications: diphenhydramine 25 mg IV + acetaminophen 650-1000 mg PO; dexamethasone added for Grade 2+ IRR management; SKIN REACTIONS AND GvHD: mogamulizumab causes severe cutaneous adverse reactions (Stevens-Johnson syndrome SJS, toxic epidermal necrolysis TEN BBW; Grade 3-4 ~1%); unique consideration for CTCL patients (cutaneous T-cell lymphoma): distinguishing disease progression from mogamulizumab-associated inflammatory skin rash requires careful clinical-dermatopathologic assessment; TRANSPLANT CONSIDERATION: mogamulizumab CCR4+ Treg depletion can cause GvHD if patient undergoes allogeneic SCT after mogamulizumab — minimum 6-month washout recommended before allo-SCT; EHS INSIGHT NULL: CAS 1159266-37-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first CCR4 antibody absent; first POTELLIGENT defucosylated antibody US absent; CCR4+ Treg depletion absent; transplant GvHD risk absent; MAVORIC absent; H360 absent; NIOSH HD Cat 1 absent; 40F Stanford University Medical Center Stanford CA dermatology-hematology pharmacist mogamulizumab 11yr).

Integrating Glyphward into Mogamulizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mogamulizumab CAS 1159266-37-1 monitoring data ingestion point — before Cority at Kyowa Kirin Inc. Bedminster NJ, before VelocityEHS at Kyowa Kirin Co. Ltd Tokyo Japan, and before EHS Insight at Stanford University Medical Center Stanford CA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-EIGHTH MECHANISM CLASS — FIRST CCR4 (C-C CHEMOKINE RECEPTOR TYPE 4) ANTIBODY EVER FDA APPROVED (BLA 761051 August 8 2018) + FIRST DEFUCOSYLATED ANTIBODY PRODUCED BY POTELLIGENT (FUT8-KO CHO) EVER FDA APPROVED IN THE US (N297 afucosylation; ~100× enhanced FcγRIIIa affinity; ~100× enhanced ADCC; seminal proof-of-concept for Fc glycoengineering in humans) + CCR4+ TREG DEPLETION MECHANISM (intratumoral CCR4+ Foxp3+ Treg ADCC → immunosuppression relief) + MAVORIC PFS HR 0.53 (7.7 vs 3.1 months; first Phase 3 to beat vorinostat in MF/SS) [5 pts]; Kyowa Kirin Bedminster NJ + Kyowa Kirin Tokyo Japan + Stanford Medical Center Stanford CA [3 pts]; first CCR4 absent; POTELLIGENT defucosylation absent; CCR4+ Treg depletion absent; MAVORIC absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mogamulizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan mogamulizumab with fifty-eighth-class first-ccr4-antibody potelligent-defucosylated context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_eighth_class_first_ccr4_antibody_ever_first_potelligent_defucosylated_antibody_us_fut8_ko_cho_n297_afucosylation_100x_adcc_ccr4_treg_depletion_mavoric_pfs_hr_0_53_kyowa_kirin_bla_761051"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_eighth_class,
    #                    first_ccr4_antibody_ever, first_potelligent_defucosylated_us,
    #                    ccr4_treg_depletion, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_mogamulizumab("1159266-37-1", 0.00039))
    print(r)
    # {'hd_category': 1, 'fifty_eighth_class': True,
    #  'first_ccr4_antibody_ever': True,
    #  'first_potelligent_defucosylated_us': True,
    #  'ccr4_treg_depletion': True,
    #  'h360_absent': True}